Pfizer Remains Flexible On Consumer Health In Restructuring
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
The adage "the more things change, the more they stay the same" may come to mind for Pfizer's consumer business: it will be a standalone division as part of a restructuring that takes effect in January but it's still for sale.
You may also be interested in...
Pfizer Deals Consumer Health Its Own Hand, Plays Waiting Game For Bids
By setting up Pfizer Consumer Healthcare to have sales and earnings results reported separately, pharma giant could be making the division's assets more visible to potential buyers. Its sales pitch: "With a strong portfolio of global brands that span health and wellness, the company believes this business is well positioned to continue its growth."
Pfizer Plays Up Its In-house Potential, Avoids M&A Talk
Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.